Cloudbreak Pharma & Santen Pharmaceutical Unite, CBT-001 Rights Granted For SE Asia

Cloudbreak Pharma, a biotech firm specializing in clinical ophthalmology, has forged a licensing deal with Santen Pharmaceutical, a leading Japanese pharma company. This partnership focuses on the development, manufacturing, and commercialization of Cloudbreak's experimental drug, CBT-001, across Southeast Asia, encompassing countries like Japan, Korea, Vietnam, Thailand, Malaysia, the Philippines, Singapore, and Indonesia. As part of the agreement, Cloudbreak Pharma is set to receive up to US$91 million, including an initial down payment and milestone-based payments. Additionally, the company will earn a double-digit percentage of the net sales from CBT-001 as royalty.

In late November 2023, Cloudbreak Pharma applied to list on the Main Board of the Stock Exchange of Hong Kong. After the application’s six-month validity period expired, they renewed it in May 2024, with UBS Group, CCB International, and Huatai International acting as joint sponsors. Previously, market reports suggested Cloudbreak Pharma aimed to raise US$200 million through this listing. As per the latest preliminary prospectus, Cloudbreak Pharma reported an operating loss of approximately US$37.215 million for 2023, an increase from the US$23.013 million loss in 2022.